摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-甲基-3,4-二氢-1(2H)-喹啉甲酰氯 | 103661-43-4

中文名称
8-甲基-3,4-二氢-1(2H)-喹啉甲酰氯
中文别名
1(2H)-喹啉羰基氯化,3,4-二氢-8-甲基-(9CI)
英文名称
8-methyl-3,4-dihydroquinoline-1(2H)-carbonyl chloride
英文别名
8-methyl-3,4-dihydro-2H-quinoline-1-carbonyl chloride
8-甲基-3,4-二氢-1(2H)-喹啉甲酰氯化学式
CAS
103661-43-4
化学式
C11H12ClNO
mdl
——
分子量
209.675
InChiKey
WAJBCWMYOGKSPT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    14
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    20.3
  • 氢给体数:
    0
  • 氢受体数:
    1

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    8-甲基-3,4-二氢-1(2H)-喹啉甲酰氯N-甲基苄胺N,N-二甲基丙烯基脲正丁基锂三乙胺二异丙胺 作用下, 以 四氢呋喃乙腈 为溶剂, 反应 2.0h, 生成 (±)-2,11-dimethyl-1-phenyl-1,2,4,5,6,7-hexahydro-3H-benzo[e][1,3]diazonin-3-one
    参考文献:
    名称:
    通过金属尿素迁移环扩展的中环氮杂环。
    摘要:
    简单的苯并稠合的氮杂环(二氢吲哚,四氢喹啉及其同系物)在N,N'-二甲基丙稀酰胺(DMPU)的存在下,通过其苄基脲衍生物与二异丙基氨基化锂(LDA)的去质子化而经历迁移环扩展。反应的产物是苯并二氮杂,、苯并二氮杂s及其同系物,环大小为8-12。该反应容许一定范围的取代基图案和类型,并且可以表现出对映特异性或非对映选择性。这些难以获得的中环氮杂环的有效合成迅速产生了相当大的复杂性。
    DOI:
    10.1002/anie.201605714
  • 作为产物:
    参考文献:
    名称:
    Substituted tetrahydroquinolines as potent allosteric inhibitors of reverse transcriptase and its key mutants
    摘要:
    Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are key elements of multidrug regimens, called HAART (Highly Active Antiretroviral Therapy), that are used to treat HIV-1 infections. Elucidation of the structure-activity relationships of the thiocarbamate moiety of the previous published lead compound 2 provided a series of novel tetrahydroquinoline derivatives as potent inhibitors of HIV-1 RT with nanomolar intrinsic activity on the WT and key mutant enzymes and potent antiviral activity in infected cells. The SAR optimization, mutation profiles, preparation of compounds, and pharmacokinetic profile of compounds are described. (C) 2009 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2009.07.031
点击查看最新优质反应信息

文献信息

  • US4593101A
    申请人:——
    公开号:US4593101A
    公开(公告)日:1986-06-03
  • Medium-Ring Nitrogen Heterocycles through Migratory Ring Expansion of Metalated Ureas
    作者:Jessica E. Hall、Johnathan V. Matlock、John W. Ward、Katharine V. Gray、Jonathan Clayden
    DOI:10.1002/anie.201605714
    日期:2016.9.5
    benzo‐fused nitrogen heterocycles (indolines, tetrahydroquinolines, and their homologues) undergo migratory ring expansion through deprotonation of their benzylic urea derivatives with lithium diisopropylamide (LDA) in the presence of N,N′‐dimethylpropylideneurea (DMPU). The products of the reactions are benzodiazepines, benzodiazocines, and their homologues, with ring sizes of 8–12. The reactions tolerate a
    简单的苯并稠合的氮杂环(二氢吲哚,四氢喹啉及其同系物)在N,N'-二甲基丙稀酰胺(DMPU)的存在下,通过其苄基脲衍生物与二异丙基氨基化锂(LDA)的去质子化而经历迁移环扩展。反应的产物是苯并二氮杂,、苯并二氮杂s及其同系物,环大小为8-12。该反应容许一定范围的取代基图案和类型,并且可以表现出对映特异性或非对映选择性。这些难以获得的中环氮杂环的有效合成迅速产生了相当大的复杂性。
  • Substituted tetrahydroquinolines as potent allosteric inhibitors of reverse transcriptase and its key mutants
    作者:Dai-Shi Su、John J. Lim、Elizabeth Tinney、Bang-Lin Wan、Mary Beth Young、Kenneth D. Anderson、Deanne Rudd、Vandna Munshi、Carolyn Bahnck、Peter J. Felock、Meiqing Lu、Ming-Tain Lai、Sinoeun Touch、Gregory Moyer、Daniel J. DiStefano、Jessica A. Flynn、Yuexia Liang、Rosa Sanchez、Sridhar Prasad、Youwei Yan、Rebecca Perlow-Poehnelt、Maricel Torrent、Mike Miller、Joe P. Vacca、Theresa M. Williams、Neville J. Anthony
    DOI:10.1016/j.bmcl.2009.07.031
    日期:2009.9
    Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are key elements of multidrug regimens, called HAART (Highly Active Antiretroviral Therapy), that are used to treat HIV-1 infections. Elucidation of the structure-activity relationships of the thiocarbamate moiety of the previous published lead compound 2 provided a series of novel tetrahydroquinoline derivatives as potent inhibitors of HIV-1 RT with nanomolar intrinsic activity on the WT and key mutant enzymes and potent antiviral activity in infected cells. The SAR optimization, mutation profiles, preparation of compounds, and pharmacokinetic profile of compounds are described. (C) 2009 Elsevier Ltd. All rights reserved.
查看更多